UNSPSC 51111863: Octreotide

This classification denotes a somatostatin receptor agonist with the molecular formula C49H66N10O10S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RWM8CCW8GP, chemically known as l-cysteinamide, d-phenylalanyl-l-cysteinyl-l-phenylalanyl-d-tryptophyl-l-lysyl-l-threonyl-n-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (r-(r*,r*))- but generally known as octreotide, which bears US NIH Compound Identifier 383414.

UNSPSC 51111863 Octreotide is a Commodity code covering a specific pharmaceutical product—in this case, a synthetic somatostatin analog used to treat acromegaly, neuroendocrine tumors, and variceal bleeding. State and local governments procure octreotide and related pharmaceuticals through cooperative purchasing agreements that aggregate demand across multiple jurisdictions and healthcare delivery systems, leveraging volume discounts and standardized pricing structures. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) exemplifies this approach, administering contracts that serve state agencies, local health facilities, and participating municipalities across multiple states. Procurement under this code focuses on establishing master agreements with manufacturers or authorized distributors who commit to specific pricing, compliance with Good Manufacturing Practices and the Drug Supply Chain Security Act, and integration with authorized wholesale partners such as AmerisourceBergen (Cencala), Cardinal Health, and Morris & Dickson.

MMCAP, operating under Minnesota's Department of Administration Office of State Procurement, posted the most recent relevant opportunity on January 20, 2026—an RFP for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026 and contract effectiveness targeted for July 1, 2026. The solicitation requires vendors to submit detailed product specifications including National Drug Codes, SKUs, and UPCs; maintain relationships with at least two of three authorized wholesalers; and accept a 3 percent administrative fee on all purchases. Evaluation weighs price competitiveness at 75 percent, with secondary criteria addressing pricing format flexibility, EDI capability, and administrative compliance. The contract runs two years for new vendors with optional MMCAP extensions, or aligns with incumbent agreements through June 30, 2028. No specific budget range is disclosed, but vendors should anticipate performance penalties of $200 to $1,500 per violation for late reporting or missed onboarding.